InVitro International reports developments in non-animal in vitro safety testing for industrial customers. The company offers validated non-animal test methods and serves markets that include cosmetics, chemical companies, and adhesives manufacturers, with recurring updates tied to animal-welfare policy and regulatory acceptance of in vitro test results.
News for IVRO commonly covers quarterly and fiscal sales, net income, profitability trends, global demand for alternatives to animal testing, and corporate growth initiatives. Company announcements also discuss strategic planning, advisory relationships, and the broader shift from animal-based safety data toward in vitro testing methods.
InVitro International reported positive second quarter FY '24 results with sales of $210,615, up 5.8% from the same period in FY '23, and net income of $47,674. First half FY '24 sales increased 3.4% to $422,240, with a net income of $65,342 compared to losses in FY '23. The company is planning an uplisting to OTCQB to enhance visibility and credibility with potential M&A targets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
InVitro International (OTC PINK:IVRO) announced its pursuit of strategic partnerships through ongoing Letter of Intent discussions. While outcomes remain uncertain, this move aligns with the company’s goal to advance non-animal testing. Following a robust 3rd Quarter of FY 2021, sales surged by 51% compared to the 2nd Quarter, accompanied by a cash reserve increase to $1.3 million. The company specializes in non-animal testing methods, offering technologies with global reach.
InVitro International (OTC PINK:IVRO) reported Q3 FY 2021 revenues of $310,700, a 35% increase year-over-year, and net income of $87,644. Year-to-date net income is $97.7K, up 17% from last year. Cash reserves stand at approximately $1.3M, bolstered by PPP loans. The company aims to enhance its mission of promoting non-animal testing methods, aligning with growing public sentiment against animal testing, amid recent legislative changes in multiple U.S. states.
InVitro International (OTC PINK:IVRO) reported a net income of $10,094 for the first half of fiscal 2021, a stark decline of 86% compared to $71,950 in the prior year. The company faced a net loss of $57,704 in the second quarter ending March 31, 2021. YTD revenues decreased by 32% to $406,365. Despite Covid-19's impact, IVRO is optimistic about recovery as March sales approached the combined revenues of previous months. The company's in vitro testing technology has gained acceptance in 37 countries, aligning with a global trend against animal testing.
InVitro International (IVRO) reported a net income of $67,663 for Q1 2021, reflecting a 40% increase from $48,177 in Q1 2020. This growth was attributed to a forgivable PPP loan charge, despite revenue declines due to Covid-19. The company aims to reduce animal testing through its plant-based predictive technology, recently accepted by OECD in 37 countries. New partnerships for testing and adjustments in China’s animal testing regulations signal potential growth. The company has added experienced board member Steven Pitassi to enhance fundraising efforts.